There are currently a number of pharmaceutical or device-based
heart failure therapies in clinical use, with numerous promising
candidates under development. Bobby Stutz and Dr Winter of
AtCor Medical, Inc discuss how PWA assessments have the ability
to streamline and optimise HF drug development by increasing
programme efficiency, shortening project timelines, and enhancing
post-market activities.